Back to News
Market Impact: 0.2
Standard Biotools Agrees To Sell Microfluidics Business To ARCHIMED
Source: Nasdaq
M&A & RestructuringHealthcare & Biotech
Standard BioTools signed a definitive agreement to sell its Microfluidics business to ARCHIMED, a healthcare-focused investment firm. The announcement disclosed no financial terms or expected closing date.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
LAB0.20
More News
- CH Robinson to Buy RXO for $5.8B in Bet on AI Model
- BPCE acquires 7% stake in Spain’s Banco Sabadell
- Brazil Election: Bolsonaro Pushes Lula to Brink as Markets Set to Rally
- C.H. Robinson CEO Dave Bozeman on RXO $5.8B Acquisition
- Why did Mattel stock surge 5% today?
- Schneider Electric drops $22.6B on PTC as datacenter boom rains money on infra companies